Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Epigenetics - levels of control
3. The patient cancer journey-multiple impact points
4. Key translational areas for epigenetics
5. DNA methylation as cancer biomarker (1)
6. DNA methylation as cancer biomarker (2)
7. Detecting methylated DNA - NaHSO3 modification
8. DNA methylation analysis methods
9. DNA methylation
10. Patient DNA methylation - potential clinical impact
11. Gene body methylation - breast cancer vs. control
12. Epigenetic gene silencing in malignant cells
13. Progress in the management of ovarian cancer
14. CpG methylation and clinical outcome
15. Wnt pathways
16. Causes of aberrant DNA methylation in cancer
17. Stem cell targets
18. Increases in side populations seen after treatment
19. Gene expression changes in side population cells
20. PRC2 - catalyses lysine methylation on histones
21. EZH2 knockdown affects tumorigenic potential
22. EZH2 as a potential anti-cancer target
23. Epigenetic modification as drug targets
24. Epigenetic therapies
25. Epigenetic modulation of drug resistance
26. DNA methylation versus platinum resistance
27. Loss of MLH1 leads to drug resistance
28. Phase II trial of Decitabine & Carboplatin
29. Decitabine and Carboplatin in ovarian cancer
30. Effects of low doses of DNA-demethylation agents
31. Epigenetic therapies challenges
32. Epigenetics unit teams and support

Topics Covered

• Epigenetics
• levels of control
• The patient cancer journey-multiple impact points -Key translational areas for epigenetics
• DNA methylation as cancer biomarker
• DNA methylation analysis methods
• Epigenetic gene silencing in malignant cells
• CpG methylation and clinical outcome
• Causes of aberrant DNA methylation in cancer
• Stem cell targets
• EZH2 as a potential anti-cancer target
• Epigenetic modification as drug targets
• Epigenetic therapies
• DNA methylation versus platinum resistance
• Phase II trial of Decitabine & Carboplatin
• Effects of low doses of DNA-demethylation agents
• Epigenetic therapies challenges

Links

Series:

• Biomarkers

Categories:

• Cancer
• Clinical Practice
• Genetics & Epigenetics

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on September 27, 2012

Financial Disclosures

• Prof. Bob Brown has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.